UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

JNCI : Journal of the National Cancer Institute, 2023-07, Vol.115 (7), p.870-880

2023

Volltextzugriff (PDF)

Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2528-2528

2019

Volltextzugriff (PDF)

Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4113-4113

2023

Volltextzugriff (PDF)

Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3559-3559

2022

Volltextzugriff (PDF)

Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.95-95

2023

Volltextzugriff (PDF)

An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4177-TPS4177

2022

Volltextzugriff (PDF)

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.LBA490-LBA490

2023

Volltextzugriff (PDF)

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4109-4109

2021

Volltextzugriff (PDF)

A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.363-363

2021

Volltextzugriff (PDF)

Advances in the management of biliary tract cancers

Clinical advances in hematology & oncology, 2013-01, Vol.11 (1), p.28-34

2013

Volltextzugriff (PDF)

A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.TPS358-TPS358

2021

Volltextzugriff (PDF)

Novel PET/CT imaging biomarkers of CB-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory RAS wildtype (WT) colorectal cancer: A phase I/II study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3616-TPS3616

2018

Volltextzugriff (PDF)

NCCN clinical practice guidelines in oncology: hepatobiliary cancers

Journal of the National Comprehensive Cancer Network, 2009-04, Vol.7 (4), p.350

2009

Volltextzugriff (PDF)

Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4116-4116

2019

Volltextzugriff (PDF)

CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.574-574

2019

Volltextzugriff (PDF)

Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.580-580

2020

Volltextzugriff (PDF)

The association of HGF/Cmet overexpression with clinicopathologic factors in hepatocellular carcinoma

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.297-297

2015

Volltextzugriff (PDF)

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

Cancer chemotherapy and pharmacology, 2021-06, Vol.87 (6), p.779-788

2021

Volltextzugriff (PDF)

Phase I study of gemcitabine (G), dasatinib (D), and erlotinib (E) in advanced pancreatic carcinoma (PC)

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.315-315

2017

Volltextzugriff (PDF)

Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D)

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.92-92

2018

Volltextzugriff (PDF)

Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2593-2593

2017

Volltextzugriff (PDF)

Routine multiplexed mutational analysis of colorectal cancers (CRCs): A single-institution experience

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.599-599

2015

Volltextzugriff (PDF)

A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4112-4112

2018

Volltextzugriff (PDF)

A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC)

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.297-297

2014

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Humans
(9)
Emergency Medicine
(4)
Female
(4)
Male
(4)
Middle Aged
(4)
Oncology
(4)
Biological And Medical Sciences
(3)
Medical Sciences
(3)
Adult
(2)
Bicycling
(2)
Bile Ducts, Intrahepatic - Pathology
(2)
Cardiopulmonary Resuscitation
(2)
Cholangiocarcinoma
(2)
Cholangiocarcinoma - Genetics
(2)
Cycling
(2)
Defibrillation
(2)
Emergency Medical Services
(2)
Patients
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s)

Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02

Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC)

Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC)

An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC)

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate

A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate

Advances in the management of biliary tract cancers

A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC)

Novel PET/CT imaging biomarkers of CB-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory RAS wildtype (WT) colorectal cancer: A phase I/II study

NCCN clinical practice guidelines in oncology: hepatobiliary cancers

Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy

CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results

Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma

The association of HGF/Cmet overexpression with clinicopathologic factors in hepatocellular carcinoma

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers

Phase I study of gemcitabine (G), dasatinib (D), and erlotinib (E) in advanced pancreatic carcinoma (PC)

Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D)

Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer

Routine multiplexed mutational analysis of colorectal cancers (CRCs): A single-institution experience

A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance)

A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC)

The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma

Suchergebnisse filtern